FY15 results on May 12, 2015
Jubilant Life Sciences Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 12, 2015, inter-alia to consider:1. Audited Financial Results of the Company for the year ended March 31,2015,2. Recommendation of Dividend for the year ended March 31, 2015.Further, as per the Companys Insider Trading Code, the trading window for dealing in the securities of the Company would remain closed... Shareholding Pattern For March 31, 2015
Jubilant Life Sciences Ltd has informed BSE about the Shareholding Pattern as on March 31, 2015. Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Jubilant Life Sciences Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
GA Global Investments Ltd has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 Disclosure of Voting results of Postal Ballot (Clause 35A)
Jubilant Life Sciences Ltd has informed BSE regarding the details of voting results of Postal Ballot, under Clause 35A. Result of Postal Ballot
Jubilant Life Sciences Ltd has informed BSE that the members of the Company have passed the resolution, by way of Postal Ballot. Updates
Jubilant Life Sciences Ltd has informed BSE that consequent to appointment of Mr. Shyam S. Bhartia as Chairman and Managing Director of Jubilant Pharma Limited, Singapore, a wholly-owned subsidiary of Jubilant Life Sciences Limited (the Company), he has resigned from the position of Managing Director of the Company effective from March 25, 2015. In view of the above, Mr. Shyam S. Bhartia shall be Non-executive Chairman and Director of the Company. Jubilant Life Sciences receives ANDA approval for Montelukast
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated March 02, 2015, titled "Jubilant Life Sciences receives ANDA approval for Montelukast". Notice of Postal Ballot
Jubilant Life Sciences Ltd has informed BSE that the members of the Company will consider to approve the special resolution, by way of Postal Ballot. Jubilant Life Sciences receives ANDA approvals for Irbesartan and Cetirizine
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated February 24, 2015, titled "Jubilant Life Sciences receives ANDA approvals for Irbesartan and Cetirizine".